MX2023012110A - Compuestos de tienopirrol. - Google Patents
Compuestos de tienopirrol.Info
- Publication number
- MX2023012110A MX2023012110A MX2023012110A MX2023012110A MX2023012110A MX 2023012110 A MX2023012110 A MX 2023012110A MX 2023012110 A MX2023012110 A MX 2023012110A MX 2023012110 A MX2023012110 A MX 2023012110A MX 2023012110 A MX2023012110 A MX 2023012110A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- thienopyrrol
- present description
- lupus erythematosus
- pharmaceutical compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176109P | 2021-04-16 | 2021-04-16 | |
| US202163216418P | 2021-06-29 | 2021-06-29 | |
| US202263305610P | 2022-02-01 | 2022-02-01 | |
| PCT/US2022/024984 WO2022221642A1 (en) | 2021-04-16 | 2022-04-15 | Thienopyrrole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012110A true MX2023012110A (es) | 2023-10-24 |
Family
ID=81580723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012110A MX2023012110A (es) | 2021-04-16 | 2022-04-15 | Compuestos de tienopirrol. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11661431B2 (enExample) |
| EP (1) | EP4323369A1 (enExample) |
| JP (1) | JP2024513945A (enExample) |
| KR (1) | KR20230171469A (enExample) |
| AU (1) | AU2022257039B2 (enExample) |
| BR (1) | BR112023021107A2 (enExample) |
| CA (1) | CA3214808A1 (enExample) |
| CL (2) | CL2023002998A1 (enExample) |
| CO (1) | CO2023013397A2 (enExample) |
| CR (1) | CR20230478A (enExample) |
| DO (1) | DOP2023000219A (enExample) |
| IL (1) | IL307203A (enExample) |
| MX (1) | MX2023012110A (enExample) |
| PE (1) | PE20240919A1 (enExample) |
| TW (2) | TWI908382B (enExample) |
| WO (1) | WO2022221642A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202440078A (zh) | 2021-09-10 | 2024-10-16 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
| EP4619005A2 (en) * | 2022-11-18 | 2025-09-24 | The United States Government As Represented By The Department Of Veterans Affairs | Methods for treating rheumatoid arthritis using a syndecan-1 inhibitor or a syntenin-1 inhibitor |
| WO2024182811A1 (en) * | 2023-03-02 | 2024-09-06 | University Of South Florida | Compositions and methods for treating uterine leiomyomas |
| WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| GB9718833D0 (en) | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
| US6329412B1 (en) | 1997-11-04 | 2001-12-11 | Pfizer Inc | Bisamidine compounds as antiproliferative agents |
| US7825154B2 (en) | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
| RU2385865C2 (ru) | 2005-08-15 | 2010-04-10 | Айрм Ллк | Соединения и композиции в качестве миметиков тро |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| EP2044083A1 (en) | 2006-07-14 | 2009-04-08 | Genelabs Technologies, Inc. | Antiviral agents |
| CN101583598B (zh) | 2007-01-15 | 2012-09-12 | 参天制药株式会社 | 具有IκB激酶β抑制活性的新型吲哚衍生物 |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| US8354400B2 (en) | 2008-09-26 | 2013-01-15 | Eisai R&D Co., Ltd. | Benzoxazole compounds and methods of use |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| AU2012262021B2 (en) | 2011-06-01 | 2016-07-28 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| BR112013030894A2 (pt) | 2011-06-01 | 2016-08-16 | Janus Biotherapeutics Inc | moduladores do sistema imune |
| WO2013052263A2 (en) | 2011-09-16 | 2013-04-11 | Microbiotix, Inc. | Antifungal compounds |
| CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| KR101452579B1 (ko) | 2012-08-17 | 2014-10-21 | 주식회사 두산 | 신규 화합물 및 이를 포함하는 유기 전계 발광 소자 |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| KR101823488B1 (ko) | 2013-10-14 | 2018-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| US20170275287A1 (en) | 2014-08-22 | 2017-09-28 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| LT3277677T (lt) | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| WO2017075694A1 (en) | 2015-11-04 | 2017-05-11 | Simon Fraser University | Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor |
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| KR102706837B1 (ko) | 2016-04-15 | 2024-09-19 | 캔써 리서치 테크놀로지 리미티드 | Ret 키나아제 억제제로서의 헤테로사이클릭 화합물 |
| TWI746545B (zh) | 2016-04-26 | 2021-11-21 | 日商大日本住友製藥股份有限公司 | 經取代嘌呤衍生物 |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| CN109715617B (zh) | 2016-07-30 | 2022-04-19 | 百时美施贵宝公司 | 作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物 |
| AU2017311047B2 (en) | 2016-08-08 | 2021-07-22 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
| ES2902504T3 (es) | 2016-09-09 | 2022-03-28 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con piridilo |
| EP4059934B1 (en) | 2016-09-09 | 2026-07-29 | Novartis AG | Compounds and compositions as inhibitors of endosomal toll-like receptors |
| WO2019018354A1 (en) | 2017-07-18 | 2019-01-24 | Merck Patent Gmbh | ANTAGONISTS OF TLR7 / 8 AND USES THEREOF |
| CN110997670B (zh) | 2017-08-04 | 2022-11-01 | 百时美施贵宝公司 | [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物 |
| EP3661926B1 (en) | 2017-08-04 | 2022-02-23 | Bristol-Myers Squibb Company | Substituted indole compounds useful as inhibitors of tlr7/8/9 |
| JP2021035910A (ja) | 2017-11-01 | 2021-03-04 | 大日本住友製薬株式会社 | 置換プリン化合物 |
| AU2018364807B2 (en) | 2017-11-08 | 2022-05-19 | Council Of Scientific & Industrial Research | Purine based compounds as toll-like receptor 9 antagonist |
| CN111448190B (zh) | 2017-11-14 | 2023-09-26 | 百时美施贵宝公司 | 取代的吲哚化合物 |
| US12030878B2 (en) | 2017-12-15 | 2024-07-09 | Bristol-Myers Squibb Company | Substituted indole ether compounds |
| MX2020006168A (es) | 2017-12-18 | 2020-08-13 | Bristol Myers Squibb Co | Compuestos de 4-azaindol. |
| EP3728253B1 (en) | 2017-12-19 | 2024-03-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
| EA202091474A1 (ru) | 2017-12-19 | 2020-11-18 | Бристол-Маерс Сквибб Компани | Замещенные индольные соединения, применимые в качестве ингибиторов tlr |
| WO2019126081A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as tlr inhibitors |
| JP2021506862A (ja) | 2017-12-19 | 2021-02-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| JP7287967B2 (ja) | 2017-12-20 | 2023-06-06 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｌｒ阻害剤として有効なアミノインドール化合物 |
| KR102730859B1 (ko) | 2017-12-20 | 2024-11-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 및 헤테로아릴 치환된 인돌 화합물 |
| EA202091530A1 (ru) | 2017-12-20 | 2020-09-14 | Бристол-Маерс Сквибб Компани | Диазаиндольные соединения |
| JP2021507889A (ja) | 2017-12-22 | 2021-02-25 | ノバルティス アーゲー | ピラゾロピペリジン誘導体の新規な使用 |
| CN110194770B (zh) * | 2018-02-26 | 2022-08-09 | 药捷安康(南京)科技股份有限公司 | 肽酰精氨酸脱亚胺酶抑制剂及其用途 |
| WO2019220390A1 (en) | 2018-05-18 | 2019-11-21 | Novartis Ag | Crystalline forms of a tlr7/tlr8 inhibitor |
| SG11202100818RA (en) | 2018-07-31 | 2021-02-25 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| ES2963696T3 (es) | 2018-10-24 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos diméricos de indol sustituidos |
| US12172995B2 (en) | 2018-10-24 | 2024-12-24 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
| US20220213099A1 (en) | 2019-05-07 | 2022-07-07 | Bristol-Myers Squibb Company | Prodrug compounds |
| KR102904576B1 (ko) | 2019-05-09 | 2025-12-24 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 벤즈이미다졸론 화합물 |
| EP3972636A4 (en) | 2019-05-23 | 2023-08-02 | The University Of Montana | VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDS |
| TW202115083A (zh) * | 2019-09-27 | 2021-04-16 | 大陸商南京藥捷安康生物科技有限公司 | 肽醯精胺酸脫亞胺酶抑制劑及其用途 |
| WO2021067326A1 (en) * | 2019-10-01 | 2021-04-08 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| CN114829350B (zh) | 2019-10-04 | 2024-05-28 | 百时美施贵宝公司 | 经取代的咔唑化合物 |
| JP7652772B2 (ja) | 2019-11-01 | 2025-03-27 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ピラゾール化合物 |
| US20240024308A1 (en) | 2020-05-14 | 2024-01-25 | Merck Healthcare Kgaa | Tlr7/8 antagonists for the treatment of coronavirus infections |
| JP7751597B2 (ja) | 2020-06-11 | 2025-10-08 | ブリストル－マイヤーズ スクイブ カンパニー | 皮膚エリテマトーデスを治療するためにプレドニゾロンまたはヒドロキシクロロキンと組み合わせるｔｌｒ７阻害剤 |
| KR20230027212A (ko) | 2020-06-22 | 2023-02-27 | 브리스톨-마이어스 스큅 컴퍼니 | 류마티스 관절염의 치료 방법 |
| WO2022022489A1 (zh) | 2020-07-27 | 2022-02-03 | 江苏恒瑞医药股份有限公司 | 吲哚稠环类衍生物、其制备方法及其在医药上的应用 |
| CN114075219B (zh) | 2020-08-14 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 喹啉稠环类衍生物、其制备方法及其在医药上的应用 |
| CN114075212B (zh) | 2020-08-14 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 稠合三环类衍生物、其制备方法及其在医药上的应用 |
| EP4200015B1 (en) | 2020-08-19 | 2026-04-29 | Bristol-Myers Squibb Company | Substituted heteroaryl compounds useful as inhibitors of tlr9 |
| EP4253387A4 (en) | 2020-11-26 | 2024-05-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused tricyclic compound, preparation method therefor and application thereof in medicine |
| EP4267560A1 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | 6-substituted indole compounds |
| EP4267559A1 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Substituted indole compounds |
-
2022
- 2022-04-15 US US17/721,636 patent/US11661431B2/en active Active
- 2022-04-15 IL IL307203A patent/IL307203A/en unknown
- 2022-04-15 EP EP22721581.1A patent/EP4323369A1/en active Pending
- 2022-04-15 KR KR1020237039381A patent/KR20230171469A/ko active Pending
- 2022-04-15 WO PCT/US2022/024984 patent/WO2022221642A1/en not_active Ceased
- 2022-04-15 CR CR20230478A patent/CR20230478A/es unknown
- 2022-04-15 JP JP2023562311A patent/JP2024513945A/ja active Pending
- 2022-04-15 TW TW113138376A patent/TWI908382B/zh active
- 2022-04-15 TW TW111114449A patent/TWI861488B/zh active
- 2022-04-15 MX MX2023012110A patent/MX2023012110A/es unknown
- 2022-04-15 PE PE2023002819A patent/PE20240919A1/es unknown
- 2022-04-15 BR BR112023021107A patent/BR112023021107A2/pt unknown
- 2022-04-15 CA CA3214808A patent/CA3214808A1/en active Pending
- 2022-04-15 AU AU2022257039A patent/AU2022257039B2/en active Active
-
2023
- 2023-03-08 US US18/180,438 patent/US20230365594A1/en not_active Abandoned
- 2023-10-06 CL CL2023002998A patent/CL2023002998A1/es unknown
- 2023-10-09 DO DO2023000219A patent/DOP2023000219A/es unknown
- 2023-10-09 CO CONC2023/0013397A patent/CO2023013397A2/es unknown
-
2024
- 2024-04-24 CL CL2024001266A patent/CL2024001266A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20240919A1 (es) | 2024-04-30 |
| TW202519532A (zh) | 2025-05-16 |
| WO2022221642A1 (en) | 2022-10-20 |
| CA3214808A1 (en) | 2022-10-20 |
| TWI861488B (zh) | 2024-11-11 |
| CL2024001266A1 (es) | 2024-11-08 |
| CL2023002998A1 (es) | 2024-04-26 |
| BR112023021107A2 (pt) | 2023-12-12 |
| IL307203A (en) | 2023-11-01 |
| AU2022257039B2 (en) | 2026-06-18 |
| AU2022257039A1 (en) | 2023-10-05 |
| CR20230478A (es) | 2023-11-30 |
| JP2024513945A (ja) | 2024-03-27 |
| EP4323369A1 (en) | 2024-02-21 |
| TW202302598A (zh) | 2023-01-16 |
| US11661431B2 (en) | 2023-05-30 |
| KR20230171469A (ko) | 2023-12-20 |
| CO2023013397A2 (es) | 2023-10-30 |
| TWI908382B (zh) | 2025-12-11 |
| US20230365594A1 (en) | 2023-11-16 |
| DOP2023000219A (es) | 2023-11-15 |
| US20220389034A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000219A (es) | Compuestos de tienopirrol | |
| CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| CR20200544A (es) | Inhibidores de mcl-1 | |
| CL2020002840A1 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CL2022002695A1 (es) | Inhibidores de rip1k | |
| DOP2015000234A (es) | COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO. | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| MX2018011012A (es) | Formulaciones y dosis de uricasa pegilada. | |
| AR106768A1 (es) | Composiciones que comprenden cepas bacterianas | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CR20160203A (es) | Inhibidores de tirosina cinasa de bruton | |
| CL2011003160A1 (es) | Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras. | |
| MX2018013387A (es) | Inhibidores de la arginasa y sus aplicaciones terapeuticas. | |
| BR112016008409A2 (pt) | Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2 | |
| EA201690810A1 (ru) | Мягкие пастилки, содержащие экстракт куркумы | |
| MX394857B (es) | Composicion farmaceutica para administracion oral que comprende enzalutamida. | |
| WO2020044119A3 (en) | Oral formulations of lavender and cannabinoids | |
| MX2022006903A (es) | Productos orales con irritacion reducida. | |
| BR112017010933A2 (pt) | composição farmacêutica | |
| CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| MX390011B (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. |